Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/38884 |
Resumo: | Responses to drugs are influenced by multiple factors, including health status, environmental influences, and genetic characteristics. The bioavailability of a drug can vary widely among individuals with a similar weight under the same drug dosage, which might result in toxicity and adverse drug reactions (ADRs). Genetic polymorphisms are known causes of interindividual differences in disease risk and treatment response in humans. In fact, a relevant number of associations between human genetic variants and predisposition to adverse events were described for diverse kinds of drug interactions, involving hundreds of proteins like receptors, transporters, and metabolizing enzymes. In this way, Pharmacogenetics and Pharmacogenomics emerged aiming to determine the genetic component responsible for drug response. A particular attention is showed if a treatment benefits (or harms) a particular subgroup, considering the interaction between treatment and genetic background. In this scenario, researchers have focused on better understanding personalized medicine, which holds the potential to maximize drug efficiency and minimize toxic effects. This review aims to introduce some principles, perspectives, and clinical applications of pharmacogenetics, emphasizing important findings and clinical applications that may contribute to therapeutical improvement. |
id |
UNIFEI_bf7c4b512686e7a0f7564e89a214e768 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/38884 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapyFarmacogenómica: una oportunidad para una farmacoterapia más segura y eficienteFarmacogenômica: uma oportunidade para uma farmacoterapia mais segura e eficientePharmacogeneticsPharmacogenomicsAdverse drug reactionsGenetic polymorphismsPersonalized medicine.Polimorfismos genéticosFarmacogenéticaFarmacogenômicaReações adversas a medicamentosMedicina personalizada.Polimorfismos genéticosFarmacogenéticaFarmacogenómicaLas reacciones adversas a medicamentosMedicina personalizada.Responses to drugs are influenced by multiple factors, including health status, environmental influences, and genetic characteristics. The bioavailability of a drug can vary widely among individuals with a similar weight under the same drug dosage, which might result in toxicity and adverse drug reactions (ADRs). Genetic polymorphisms are known causes of interindividual differences in disease risk and treatment response in humans. In fact, a relevant number of associations between human genetic variants and predisposition to adverse events were described for diverse kinds of drug interactions, involving hundreds of proteins like receptors, transporters, and metabolizing enzymes. In this way, Pharmacogenetics and Pharmacogenomics emerged aiming to determine the genetic component responsible for drug response. A particular attention is showed if a treatment benefits (or harms) a particular subgroup, considering the interaction between treatment and genetic background. In this scenario, researchers have focused on better understanding personalized medicine, which holds the potential to maximize drug efficiency and minimize toxic effects. This review aims to introduce some principles, perspectives, and clinical applications of pharmacogenetics, emphasizing important findings and clinical applications that may contribute to therapeutical improvement. Las respuestas a las drogas están influenciadas por múltiples factores, incluido el estado de salud, las influencias ambientales y las características genéticas. La biodisponibilidad de un fármaco puede variar ampliamente entre individuos de peso similar bajo la misma cantidad de fármaco, lo que puede provocar toxicidad y reacciones adversas a drogas (RADs). Los polimorfismos genéticos son causas conocidas de las diferencias interindividuales en el riesgo de desarrollar enfermedades y la respuesta al tratamiento farmacológico. Se ha descrito un número relevante de asociaciones entre variantes genéticas humanas y predisposición a los eventos adversos para diferentes tipos de interacciones medicamentosas, involucrando a las proteinas como receptores, transportadores y enzimas metabolizadoras. Así, la Farmacogenética y la Farmacogenómica surgieron con el objetivo de determinar el componente genético responsable de la respuesta a las drogas. Se presta la debida atención a si un tratamiento beneficia (o perjudica) a un subgrupo de personas, considerando una interacción entre el tratamiento y los antecedentes genéticos de la población. En este escenario, los investigadores se han centrado en comprender mejor la medicina personalizada que tiene el potencial de maximizar la eficacia de las drogas y minimizar los efectos tóxicos. Esta revisión tiene como objetivo presentar algunos principios, perspectivas y aplicaciones clínicas de la farmacogenética, enfatizando hallazgos importantes y aplicaciones clínicas que pueden contribuir a la mejora terapéutica.As respostas aos fármacos são influenciadas por múltiplos fatores, incluindo estado de saúde, influências ambientais e características genéticas. A biodisponibilidade de um fármaco pode variar amplamente entre indivíduos com peso semelhante sob a mesma quantidade de fármaco, o que pode resultar em toxicidade e reações adversas aos fármacos (RAFs). Polimorfismos genéticos são causas conhecidas para as diferenças interindividuais no risco para desenvolvimento de doenças e na resposta ao tratamento farmacológico. Um número relevante de associações entre variantes genéticas humanas e predisposição aos eventos adversos tem sido descrito para diferentes tipos de interações medicamentosas, envolvendo centenas de proteínas tais como receptores, transportadores e enzimas metabolizadoras. Dessa forma, a Farmacogenética e a Farmacogenômica surgiram com o objetivo de determinar o componente genético responsável pela resposta aos fármacos. Uma atenção é dada para se um tratamento beneficia (ou prejudica) um determinado subgrupo de pessoas, considerando uma interação entre o tratamento e o histórico genético da população. Nesse cenário, os pesquisadores têm se concentrado em entender melhor a medicina personalizada que tem o potencial de maximizar uma eficiência dos fármacos e minimizar os efeitos tóxicos. Esta revisão visa apresentar alguns princípios, perspectivas e aplicações clínicas da farmacogenética, enfatizando achados importantes e aplicações clínicas que podem contribuir para o aprimoramento terapêutico.Research, Society and Development2022-12-19info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3888410.33448/rsd-v11i17.38884Research, Society and Development; Vol. 11 No. 17; e44111738884Research, Society and Development; Vol. 11 Núm. 17; e44111738884Research, Society and Development; v. 11 n. 17; e441117388842525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/38884/32045Copyright (c) 2022 Guilherme Carneiro Montes; Graziele Freitas de Bem; Fabrícia Lima Fontes-Dantashttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMontes, Guilherme Carneiro Bem, Graziele Freitas de Fontes-Dantas, Fabrícia Lima 2022-12-28T13:53:48Zoai:ojs.pkp.sfu.ca:article/38884Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:52:23.970232Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy Farmacogenómica: una oportunidad para una farmacoterapia más segura y eficiente Farmacogenômica: uma oportunidade para uma farmacoterapia mais segura e eficiente |
title |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy |
spellingShingle |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy Montes, Guilherme Carneiro Pharmacogenetics Pharmacogenomics Adverse drug reactions Genetic polymorphisms Personalized medicine. Polimorfismos genéticos Farmacogenética Farmacogenômica Reações adversas a medicamentos Medicina personalizada. Polimorfismos genéticos Farmacogenética Farmacogenómica Las reacciones adversas a medicamentos Medicina personalizada. |
title_short |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy |
title_full |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy |
title_fullStr |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy |
title_full_unstemmed |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy |
title_sort |
Pharmacogenomics: an opportunity for safer and efficient pharmacotherapy |
author |
Montes, Guilherme Carneiro |
author_facet |
Montes, Guilherme Carneiro Bem, Graziele Freitas de Fontes-Dantas, Fabrícia Lima |
author_role |
author |
author2 |
Bem, Graziele Freitas de Fontes-Dantas, Fabrícia Lima |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Montes, Guilherme Carneiro Bem, Graziele Freitas de Fontes-Dantas, Fabrícia Lima |
dc.subject.por.fl_str_mv |
Pharmacogenetics Pharmacogenomics Adverse drug reactions Genetic polymorphisms Personalized medicine. Polimorfismos genéticos Farmacogenética Farmacogenômica Reações adversas a medicamentos Medicina personalizada. Polimorfismos genéticos Farmacogenética Farmacogenómica Las reacciones adversas a medicamentos Medicina personalizada. |
topic |
Pharmacogenetics Pharmacogenomics Adverse drug reactions Genetic polymorphisms Personalized medicine. Polimorfismos genéticos Farmacogenética Farmacogenômica Reações adversas a medicamentos Medicina personalizada. Polimorfismos genéticos Farmacogenética Farmacogenómica Las reacciones adversas a medicamentos Medicina personalizada. |
description |
Responses to drugs are influenced by multiple factors, including health status, environmental influences, and genetic characteristics. The bioavailability of a drug can vary widely among individuals with a similar weight under the same drug dosage, which might result in toxicity and adverse drug reactions (ADRs). Genetic polymorphisms are known causes of interindividual differences in disease risk and treatment response in humans. In fact, a relevant number of associations between human genetic variants and predisposition to adverse events were described for diverse kinds of drug interactions, involving hundreds of proteins like receptors, transporters, and metabolizing enzymes. In this way, Pharmacogenetics and Pharmacogenomics emerged aiming to determine the genetic component responsible for drug response. A particular attention is showed if a treatment benefits (or harms) a particular subgroup, considering the interaction between treatment and genetic background. In this scenario, researchers have focused on better understanding personalized medicine, which holds the potential to maximize drug efficiency and minimize toxic effects. This review aims to introduce some principles, perspectives, and clinical applications of pharmacogenetics, emphasizing important findings and clinical applications that may contribute to therapeutical improvement. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-12-19 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/38884 10.33448/rsd-v11i17.38884 |
url |
https://rsdjournal.org/index.php/rsd/article/view/38884 |
identifier_str_mv |
10.33448/rsd-v11i17.38884 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/38884/32045 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 17; e44111738884 Research, Society and Development; Vol. 11 Núm. 17; e44111738884 Research, Society and Development; v. 11 n. 17; e44111738884 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052815052374016 |